How is Clostridioides difficile infection classified by severity in adults and what are the first‑line treatment options for mild‑to‑moderate, severe, and fulminant disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 16, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Classification of Clostridioides difficile Infection by Severity

Clostridioides difficile infection should be classified into three severity categories—mild-to-moderate, severe, and fulminant—using specific clinical and laboratory parameters that directly predict mortality and surgical intervention risk. 1

Mild-to-Moderate CDI

Mild-to-moderate disease is defined by:

  • WBC < 15,000 cells/mL 2, 1
  • Serum creatinine < 1.5 times baseline 2, 1
  • Diarrhea without systemic signs of severe infection 2, 1
  • May have mild abdominal pain and cramping 1

First-line treatment for mild-to-moderate CDI:

  • Oral vancomycin 125 mg four times daily for 10 days 2
  • Oral fidaxomicin 200 mg twice daily for 10 days (alternative, especially if high recurrence risk) 2
  • Metronidazole 500 mg three times daily for 10-14 days is no longer recommended as first-line therapy in adults, though it may remain reasonable for select mild cases 2, 3, 4

Severe CDI

Severe disease is characterized by any one or more of the following:

  • WBC ≥ 15,000 cells/mL 2, 1
  • Serum creatinine ≥ 1.5 mg/dL or ≥ 50% increase above baseline 2, 1
  • Serum albumin < 2.5-3.0 g/dL 1
  • Age > 65 years 1
  • Body temperature > 38.5°C 1
  • ≥ 10 bowel movements within 24 hours 1
  • Severe abdominal pain 1
  • Evidence of pseudomembranous colitis on endoscopy 1
  • ICU admission required 1

First-line treatment for severe CDI:

  • Oral vancomycin 125 mg four times daily for 10-14 days (preferred) 2
  • Oral fidaxomicin 200 mg twice daily for 10 days (alternative) 2
  • If oral route not feasible: vancomycin 500 mg per rectum (in 500 mL saline as enema) four times daily AND/OR metronidazole 500 mg IV every 8 hours 2

Fulminant CDI

Fulminant disease represents life-threatening infection with:

  • Hypotension or shock requiring vasopressors 2, 1
  • End-organ failure 1
  • Ileus 2, 1
  • Toxic megacolon 2, 1
  • Colonic perforation 1
  • Septic shock 1

Treatment for fulminant CDI:

  • Oral vancomycin 500 mg four times daily 2
  • PLUS vancomycin 500 mg per rectum (in 500 mL saline) four times daily 2
  • PLUS metronidazole 500 mg IV every 8 hours 2
  • Multidisciplinary care is mandatory including critical care, surgery, gastroenterology, and infectious disease 2, 5
  • Consider fecal microbiota transplantation if not responding to antibiotics within 2-5 days 2, 5
  • FMT should be delivered via colonoscopy or flexible sigmoidoscopy as first dose 2, 5
  • Surgical consultation for possible colectomy if medical management fails 1, 5

Recurrent CDI

Recurrent infection is defined as:

  • Return of gastrointestinal symptoms due to CDI following initial resolution 1
  • Occurring within 8 weeks after discontinuation of treatment 2, 1
  • Affects 10-30% of patients after initial therapy 1

Treatment approach for recurrent CDI:

First recurrence:

  • Repeat initial therapy with oral vancomycin or fidaxomicin 2

Second or subsequent recurrences:

  • Vancomycin oral taper and pulse regimen: 125 mg every 6 hours × 1-2 weeks, then 125 mg every 12 hours × 1 week, then 125 mg every 24 hours × 1 week, then 125 mg every 48 hours × 2-8 weeks 2
  • Fidaxomicin 200 mg twice daily for 10 days 2
  • Fecal microbiota transplantation (highly effective for multiple recurrences) 2
  • Bezlotoxumab (monoclonal antibody against toxin B) may be considered as adjunctive therapy in patients with high recurrence risk 6, 4

Critical Pitfalls to Avoid

  • Never perform "test of cure" after treatment completion—over 60% of successfully treated patients remain C. difficile positive despite clinical resolution 7
  • Do not use fidaxomicin for fulminant/complicated CDI—there are no data supporting its use in this setting 2
  • Do not delay gastroenterology consultation in severe or fulminant cases—these are medical emergencies requiring immediate multidisciplinary involvement 5
  • Consider post-infectious irritable bowel syndrome rather than recurrent CDI for mild symptoms after successful treatment 2, 7
  • Treatment response may require 3-5 days after starting therapy, but escalation can be considered sooner based on disease severity 2

References

Guideline

Classification of Clostridioides difficile Infection by Severity

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Clostridioides difficile Infection: Update on Management.

American family physician, 2020

Guideline

Management of C. difficile Infection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

C. difficile Toxin Testing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the management approach for a patient with a suspected or confirmed Clostridioides (C.) difficile infection?
What is the recommended empirical treatment for a patient with a suspected Clostridioides difficile (C. Diff) infection?
What is the recommended antibiotic treatment for a patient with confirmed Clostridioides (C.) difficile infection?
Is Augmentin (amoxicillin-clavulanate) an effective treatment for a patient with Clostridioides difficile (C. difficile) infection?
What is the management plan for a patient with a positive Clostridioides difficile (C. diff) test at a nursing facility?
I am three weeks after a miscarriage, serum β‑hCG is 6 IU/L, endometrial thickness is 8 mm, and I have occasional pink/red/brown spotting after walking; is this normal and what follow‑up is needed?
What is the therapeutic plasma concentration range for lamotrigine (Lamictal)?
What is the recommended medication regimen for an adult with compensated or decompensated cirrhosis to treat the underlying etiology, prevent portal‑hypertensive complications, and manage ascites, hepatic encephalopathy, and infection?
What is the recommended protocol for initiating contraception in a reproductive‑aged woman, including screening for estrogen contraindications and selecting an appropriate method?
A patient with a known germ‑cell tumor presents with unexplained weight loss; what diagnostic evaluation and management should be undertaken?
What is the appropriate dosing, dilution, and monitoring protocol for a continuous intravenous morphine infusion in an adult, both opioid‑naïve and opioid‑tolerant, including adjustments for renal or hepatic impairment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.